QC
HZNP

Quadrature Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Quadrature Capital’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-43,790
Closed -$721K – 816
2016
Q2 		$721K Buy
+43,790
New +$708K 0.05% 292
2015
Q4 		– Sell
-52,043
Closed -$1.03M – 561
2015
Q3 		$1.03M Buy
+52,043
New +$1.64M 0.34% 93

Other funds holding HZNP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Quadrature Capital's HZNP Position: Q3 2016 in Review

Quadrature Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2016, closing a stake of 43,790 shares — an estimated $721K sold.

Quadrature Capital first reported a position in HZNP in Q3 2015 and held it in 2 quarters. The position peaked at $1.03M in Q3 2015. 232 funds tracked by Wall St. Rank hold HZNP as of Q3 2016.

  • Quadrature Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2016 after selling out during the quarter.
  • Quadrature Capital sold 43,790 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2016, an estimated $721K.
  • Quadrature Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2015 and held it in 2 quarters.
  • Quadrature Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.03M in Q3 2015.
  • 232 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2016.

Based on Quadrature Capital's 13F filing for Q3 2016, filed 10 Nov 2016.